Analysts’ Viewpoint Glioblastoma Multiforme (GBM) Treatment Market Scenario
Since active COVID-19 infection cases are declining in most countries except for regions such as Shanghai in China, participants in the glioblastoma multiforme (GBM) treatment market are witnessing an uptick in market growth. However, poor medical outcomes in GBM patients are discouraging patients to seek medical treatment. Hence, market players should offer better reimbursement packages to individuals to encourage GBM patients for seeking medical treatment. Healthcare companies should increase awareness about early diagnosis of GBM through marketing in order to reduce its severity in potential patients. In addition, healthcare companies should invest in R&D by seeking funds from cancer organizations to develop better treatment alternatives in chemo, drugs, and radiotherapy to improve patient outcomes.
Mature healthcare markets such as the U.S. in North America are creating stable revenue streams for market stakeholders. North America is projected to be a highly lucrative region for the glioblastoma multiforme (GBM) treatment market throughout the assessment tenure. Major healthcare companies are bullish on investments in R&D for increasing the availability of treatment options across the region.
Leading-edge and advanced healthcare infrastructure in the U.S. has aided in the development of drug repurposing for the treatment of glioblastoma multiforme. Moreover, favorable regulatory environment is a key factor propelling the glioblastoma multiforme (GBM) treatment market in North America. A positive legal and regulatory environment facilitates the development and early acceptance of GBM medications.
Since glioblastoma multiforme is a potentially life-threatening autoimmune disorder, healthcare stakeholders in the glioblastoma multiforme (GBM) treatment market are striving to ensure the availability of radiation therapy and chemotherapy amid the ongoing COVID-19 pandemic. Pharmaceutical companies have been working at breakneck speeds to maintain robust supply for life-altering therapeutics, medications, and other drugs at hospitals, ambulatory surgical centers, and clinics.
Healthcare companies are taking data-driven decisions before investing in R&D for drug development and other therapeutic innovations. They are capitalizing on government stimulus packages in order to keep economies going. Relaxations in pandemic related restrictions are helping to increase footfalls in healthcare facilities.
The global glioblastoma multiforme (GBM) treatment market is increasingly sensitive toward R&D, manufacturing costs, as well as market price, since the market is challenged with high morbidity and mortality rates. For small- or medium-scale healthcare companies, glioblastoma multiforme treatment research & development requires significant amount of resources and capital. Such trends are inhibiting market growth.
Glioblastoma multiforme (GBM) treatment is a commonly found cancer but it is associated with poor medical outcomes, owing to its aggressive nature for metastasis in the human body. These findings are triggering the need for high investment in R&D activities. Hence, uncertainty over expected profit deters companies from entering the market. Thus, companies should work closely with major healthcare organizations to increase funding for R&D.
The rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the glioblastoma multiforme (GBM) treatment market. However, it has been found that survival rate of patients suffering from GBM is relatively poor.
Very few patients survive for 2.5 to 5 years following diagnosis. According to the data published by the Centers for Disease Control and Prevention (CDC), a national public health agency of the U.S., 90% of the adult patients with GBM die within 24 months after diagnosis. Moreover, the incidence of GBM ranges from 0.59 to 5 per 100,000 individuals, and this rate is increasing in multiple countries across the globe. The figures above indicate that the demand for treatment is likely to increase exponentially, which, in turn, is projected to augment the global glioblastoma multiforme (GBM) treatment market.
Companies in the glioblastoma multiforme (GBM) treatment market are expected to join forces with researchers from universities to fast-track the drug development of glioblastoma. Such collaborations are encouraging international cancer organizations to fund R&D activities. Pharmaceutical companies are entering into cooperation agreement with research centers for the clinical development of radiopharmaceutical therapy, for the treatment of glioblastoma multiforme.
Innovative healthcare therapeutics companies are announcing the early results from phase 1 trials of its glioblastoma multiforme treatment alternative. The treatment was developed using peptide inhibitor to fight against recurrent high-grade gliomas.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 1.61 Bn |
|
Market Forecast Value in 20231 |
US$ 3.72 Bn |
|
Growth Rate (CAGR) |
8.1% |
|
Forecast Period |
2021–2028 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
| Treatment |
|
| End-user |
|
| Region |
|
Glioblastoma multiforme (GBM) treatment market is expected to reach the value of US$ 3.72 Bn by the end of 2028
Glioblastoma multiforme (GBM) treatment market is estimated to expand at a CAGR of 8.1% from 2021 to 2028
Glioblastoma multiforme (GBM) treatment market is driven by rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes
North America accounted for the largest share of the global glioblastoma multiforme (GBM) treatment market
Key players in the global glioblastoma multiforme (GBM) treatment market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glioblastoma Multiforme Treatment (GBM) Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, 2017–2028
5. Key Insights
5.1. Regulatory Scenario, by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry
6. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2028
6.3.1. Radiation Therapy
6.3.2. Chemotherapy
6.3.2.1. Temozolomide
6.3.2.2. Bevacizumab
6.3.2.3. Carmustine
6.3.2.4. Other Types of Chemotherapy
6.3.3. Other Treatments
6.4. Market Attractiveness Analysis, by Treatment
7. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2028
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Clinics
7.4. Market Attractiveness Analysis, By End-user
8. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, By Country/Region
9. North America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment, 2017–2028
9.2.1. Radiation Therapy
9.2.2. Chemotherapy
9.2.2.1. Temozolomide
9.2.2.2. Bevacizumab
9.2.2.3. Carmustine
9.2.2.4. Other Types of Chemotherapy
9.3. Market Value Forecast, by End-user, 2017–2028
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Clinics
9.4. Market Value Forecast, by Country, 2017–2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2028
10.2.1. Radiation Therapy
10.2.2. Chemotherapy
10.2.3. Temozolomide
10.2.4. Bevacizumab
10.2.5. Carmustine
10.2.6. Other Types of Chemotherapy
10.2.7. Other Treatments
10.3. Market Value Forecast, by End-user, 2017–2028
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Clinics
10.4. Market Value Forecast, by Country/Sub-region, 2017–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2028
11.2.1. Radiation Therapy
11.2.2. Chemotherapy
11.2.2.1. Temozolomide
11.2.2.2. Bevacizumab
11.2.2.3. Carmustine
11.2.2.4. Other Types of Chemotherapy
11.2.3. Other Treatments
11.3. Market Value Forecast, by End-user, 2017–2028
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Clinics
11.4. Market Value Forecast, by Country/Sub-region, 2017–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By Drug Class
11.5.3. By End-user
11.5.4. By Country/Sub-region
12. Latin America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2028
12.2.1. Radiation Therapy
12.2.2. Chemotherapy
12.2.2.1. Temozolomide
12.2.2.2. Bevacizumab
12.2.2.3. Carmustine
12.2.2.4. Other Types of Chemotherapy
12.2.3. Other Treatments
12.3. Market Value Forecast, by End-user, 2017–2028
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Clinics
12.4. Market Value Forecast, by Country/Sub-region, 2017–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By Drug Class
12.5.3. By End-user
12.5.4. By Country/Sub-region
13. Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2028
13.2.1. Radiation Therapy
13.2.2. Chemotherapy
13.2.2.1. Temozolomide
13.2.2.2. Bevacizumab
13.2.2.3. Carmustine
13.2.2.4. Other Types of Chemotherapy
13.2.3. Other Treatments
13.3. Market Value Forecast, by End-user, 2017–2028
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Clinics
13.4. Market Value Forecast, by Country/Sub-region, 2017–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By Drug Class
13.5.3. By End-user
13.5.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Merck & Co., Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Analysis
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Analysis
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Analysis
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Amgen, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Analysis
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Analysis
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sun Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Analysis
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Arbor Pharmaceuticals, LLC
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Analysis
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Amneal Pharmaceuticals
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Analysis
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Karyopharm Therapeutics, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Analysis
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Analysis
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
List of Tables
TABLE 1: Market Snapshot: Global Glioblastoma Multiforme Treatment (GBM) Market
TABLE 2: Global Prevalence of Glioblastoma Multiforme worldwide
TABLE 3: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 4: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
TABLE 5: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Geography, 2017–2031
TABLE 6: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country, 2017–2031
TABLE 7: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 8: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
TABLE 9: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031
TABLE 10: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 11: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
TABLE 12: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031
TABLE 13: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 14: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
TABLE 15: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031
TABLE 16: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 17: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
TABLE 18: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031
TABLE 19: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031
TABLE 20: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031
List of Figures
FIG. 1: Comparative Analysis: Global 3D Printing Market, by Treatment, 2021 & 2028 (%)
FIG. 2: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation
FIG. 3: Global Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class, 2020
FIG. 4: Global Glioblastoma Multiforme Treatment (GBM) Market, by Treatment, 2020
FIG. 5: Global Glioblastoma Multiforme Treatment (GBM) Market: Drivers and Restraints
FIG. 6: Porter’s Five Forces Analysis for Glioblastoma Multiforme Treatment (GBM) Market
FIG. 7: Market Attractiveness Analysis: Glioblastoma Multiforme Treatment (GBM) Market, by Region
FIG. 8: Global Glioblastoma Multiforme Treatment (GBM) Market Share Analysis of Key Players
FIG. 9: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation, by Drug Class
FIG. 10: Global Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 11: Global Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 12: Global Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 13: Global Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 14: Global Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 15: Global Lomustine Market Value (US$ Mn), 2021–2028
FIG. 16: Global Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 17: Global Tumor Treating Field (TTF) Therapy Market, 2021–2028
FIG. 18: Market Segmentation of Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class
FIG. 19: North America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 20: North America Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 21: North America Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 22: North America Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 23: North America Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 24: North America Lomustine Market Value (US$ Mn), 2021–2028
FIG. 25: North America Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 26: North America Tumor Treating Field (TTF) Therapy Market, 2021–2028
FIG. 27: Europe Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 28: Europe Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 29: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 30: Europe Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 31: Europe Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 32: Europe Lomustine Market Value (US$ Mn), 2021–2028
FIG. 33: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 34: Europe Tumor Treating Field (TTF) Therapy Market, 2021–2028
FIG. 35: Asia Pacific Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 36: Asia Pacific Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 37: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 38: Asia Pacific Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 39: Asia Pacific Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 40: Asia Pacific l Lomustine Market Value (US$ Mn), 2021–2028
FIG. 41: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 42: Asia Pacific Tumor Treating Field (TTF) Therapy Market, 2021–2028
FIG. 43: Latin America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 44: Latin America Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 45: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 46: Latin America Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 47: Latin America Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 48: Latin America Lomustine Market Value (US$ Mn), 2021–2028
FIG. 49: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 50: Latin America Tumor Treating Field (TTF) Therapy Market, 2021–2028
FIG. 51: Middle East & Africa Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028
FIG. 52: Middle East & Africa Radiation Therapy Market Value (US$ Mn), 2021–2028
FIG. 53: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 54: Middle East & Africa Temozolomide Market Value (US$ Mn), 2021–2028
FIG. 55: Middle East & Africa Bevacizumab Market Value (US$ Mn), 2021–2028
FIG. 56: Middle East & Africa Lomustine Market Value (US$ Mn), 2021–2028
FIG. 57: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028
FIG. 58: Middle East & Africa Tumor Treating Field (TTF) Therapy Market, 2021–2028
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Glioblastoma Multiforme Treatment (GBM) Market Insights, 2021-2028
